Gene therapy will soon be tested on people with Alzheimer's

December 20, 1999

THE first trial to test whether gene therapy can slow the progress of Alzheimer's disease has been given the go-ahead. In theory the same technique could be used to enhance the cognitive ability of people who aren't suffering from dementia.

Alzheimer's is the most common cause of dementia in older people, killing brain cells called cholinergic neurons. As the number of elderly people in developed nations increases, it is exacting an ever more devastating toll (see Figure), so finding effective ways to treat it is a top priority.

Researchers led by Mark Tuszynski of the University of California, San Diego, are betting that a substance called nerve growth factor (NGF) will stave off dementia not only by preventing the death of cholinergenic neurons, but also by promoting new connections between the cells.

A decade of experiments on rodents and primates shows that NGF helps protect cholinergic neurons and can reverse memory loss. In September, for instance, Tuszynski's team showed that NGF gene therapy could reverse age-related neural degeneration in rhesus monkeys, with the genes remaining active for at least a year (New Scientist, 18 September, p 6).

Shortly before Christmas, the National Institutes of Health's Recombinant DNA Advisory Committee (RAC) cleared an initial safety study that will involve eight people with early Alzheimer's disease who can understand and consent to the procedure. First, the researchers will take cells called fibroblasts from the patients' skin and genetically engineer them to produce NGF by adding extra copies of the gene using a mouse leukaemia virus modified to ensure that it shouldn't trigger cancer. Then they will inject the NGF-producing cells into the base of the patients' forebrains.

Although the RAC agreed that the virus that will be used to deliver the NGF gene poses little risk, one member did question the growth factor itself. Wilma Friedman of Columbia University in New York noted that NGF can kill brain cells that carry a receptor called p75 but not another called trk. However, Tuszynski points out that cells in the basal forebrain seem to have both receptors.

The main goal of the trial is to assess the maximum dose of modified cells that can be safely injected. But Tuszynski will also look to see if the disease progresses more slowly than normal. "We think there is a direct potential for benefit," he says.

The researchers have had to resort to gene therapy because NGF injected into the blood stream doesn't readily cross the blood-brain barrier. However, any genetic technique that affects brain function has the potential to generate controversy. Earlier this year, for instance, when Joe Tsien and his colleagues at Princeton University in New Jersey created transgenic mice with improved memories by boosting levels of the gene for a receptor on the surface of brain cells called NMDA, there was widespread speculation about using the human version of the gene to engineer "supersmart" people (New Scientist, 4 September, p 15).

Tuszynski plays down these fears. "Most of these studies that demonstrate enhanced brain function with growth factors or other agents, like Tsien's, have been done to understand what the normal, physiological role of a gene is," he says. Using similar techniques to treat debilitating diseases such as Alzheimer's doesn't mean that anyone is suggesting that they should be used to improve normal human cognitive function, Tuszynski stresses.

However, Eric Juengst, a bioethicist at Case Western Reserve University in Cleveland, says that many gene therapies designed to treat disease also have potential for genetically enhancing healthy people. "This just highlights a problem that the RAC will see increasingly," he says.
-end-
Author: Nell Boyce, Washington DC

New Scientist double christmas issue: 25 December 1999/ 1 January 2000

PLEASE MENTION NEW SCIENTIST AS THE SOURCE OF THIS STORY AND, IF PUBLISHING ONLINE, PLEASE CARRY A HYPERLINK TO : http://www.newscientist.com

UK CONTACT - Claire Bowles, New Scientist Press Office, London:
Tel: +44(0)20 7331 2751 or email claire.bowles@rbi.co.uk
US CONTACT - New Scientist Washington office:
Tel: 202 452 1178 or email newscidc@idt.net


New Scientist

Related Gene Therapy Articles from Brightsurf:

Risk of AAV mobilization in gene therapy
New data highlight safety concerns for the replication of recombinant adeno-associated viral (rAAV) vectors commonly used in gene therapy.

Discovery challenges the foundations of gene therapy
An article published today in Science Translational Medicine by scientists from Children's Medical Research Institute has challenged one of the foundations of the gene therapy field and will help to improve strategies for treating serious genetic disorders of the liver.

Gene therapy: Novel targets come into view
Retinitis pigmentosa is the most prevalent form of congenital blindness.

Gene therapy targets inner retina to combat blindness
Batten disease is a group of fatal, inherited lysosomal storage disorders that predominantly affect children.

New Human Gene Therapy editorial: Concern following gene therapy adverse events
Response to the recent report of the deaths of two children receiving high doses of a gene therapy vector (AAV8) in a Phase I trial for X-linked myotubular myopathy (MTM).

Restoring vision by gene therapy
Latest scientific findings give hope for people with incurable retinal degeneration.

Gene therapy/gene editing combo could offer hope for some genetic disorders
A hybrid approach that combines elements of gene therapy with gene editing converted an experimental model of a rare genetic disease into a milder form, significantly enhancing survival, shows a multi-institutional study led by the University of Pennsylvania and Children's National Hospital in Washington, D.C.

New technology allows control of gene therapy doses
Scientists at Scripps Research in Jupiter have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing.

Gene therapy: Development of new DNA transporters
Scientists at the Institute of Pharmacy at Martin Luther University Halle-Wittenberg (MLU) have developed new delivery vehicles for future gene therapies.

Gene therapy promotes nerve regeneration
Researchers from the Netherlands Institute for Neuroscience and the Leiden University Medical Center have shown that treatment using gene therapy leads to a faster recovery after nerve damage.

Read More: Gene Therapy News and Gene Therapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.